Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study

Department of Psychiatry, the First Hospital of China Medical University, 155# Nanjing North Road, Shenyang 110001, Liaoning, PR China.
Schizophrenia Research (Impact Factor: 4.43). 03/2012; 138(1):54-7. DOI: 10.1016/j.schres.2012.02.021
Source: PubMed

ABSTRACT To evaluate the efficacy of metformin for treatment of antipsychotic-induced weight gain.
Seventy-two patients with first-episode schizophrenia who gained more than 7% of their predrug weight were randomly assigned to receive 1000 mg/d of metformin or placebo in addition to their ongoing treatment for 12 weeks using a double-blind study design. The primary outcome was change in body weight. The secondary outcomes included changes in body mass index, fasting glucose and insulin, and insulin resistance index.
Of the 72 patients who were randomly assigned, 66 (91.6%) completed treatments. The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period. Significantly more patients in the metformin group lost their baseline weight by more than 7%, which was the cutoff for clinically meaningful weight loss. Metformin was tolerated well by majority patients.
Metformin was effective and safe in attenuating antipsychotic-induced weight gain and insulin resistance in first-episode schizophrenia patients. Patients displayed good adherence to metformin.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus and depressive disorders are both common chronic diseases that increase functional disability and social burden. Cognitive impairment is a potentially debilitating feature of depression. Previous evidence has revealed that the antidiabetic drug metformin could be suitable for diabetic patients with cognitive impairment. However, there is no direct evidence from clinical studies that metformin treatment improves cognitive function in diabetic patients suffering from depression. In this study 58 participants, diagnosed with depression and type 2 diabetes mellitus, were recruited and divided into two groups: one treated with metformin and one with placebo for 24 weeks. Cognitive function, depressive behavior and diabetes improvement were evaluated. Chronic treatment with metformin for 24 weeks improved cognitive performance assessed by the Wechsler Memory Scale-Revised (WMS-R) in depressed patients with type 2 diabetes mellitus. In addition, metformin significantly improved depressive performance and changed the glucose metabolism in depressed patients with diabetes. Depressive symptoms negatively correlated with the cognitive performance in metformin-treated participants. Furthermore, associations were also observed between the parameters of blood glucose metabolism and the depression phenotype. These findings suggested that chronic treatment with metformin produced antidepressant behavioral effects, and that improved cognitive function is involved in the therapeutic outcome of metformin. The current results also raised the possibility that supplementary administration of antidiabetic medications might enhance the recovery of depression, co-morbid with type 2 diabetes mellitus, through improvements in cognitive performance.This article is protected by copyright. All rights reserved.
    Clinical and Experimental Pharmacology and Physiology 05/2014; 41(9). DOI:10.1111/1440-1681.12265 · 2.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals with serious mental illness have high rates of cardiovascular disease (CVD) risk factors and mortality. This systematic review was conducted to evaluate pharmacologic and behavioral interventions to reduce CVD risk in adults with serious mental illness.
    The Journal of Clinical Psychiatry 05/2014; 75(5):e424-e440. DOI:10.4088/JCP.13r08558 · 5.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug. Herein, we discuss the potential mechanisms by which metformin decreases appetite and opposes unfavorable fat storage in peripheral tissues. Recent findings Many individuals struggle to maintain clinically relevant weight loss from lifestyle and bariatric surgery interventions. Long-term follow-up from the Diabetes Prevention Program demonstrates that metformin produces durable weight loss, and decreased food intake by metformin is the primary weight loss mechanism. Although the effect of metformin on appetite is likely to be multifactorial, changes in hypothalamic physiology, including leptin and insulin sensitivity, have been documented. In addition, novel work in obesity highlights the gastrointestinal physiology and circadian rhythm changes by metformin as not only affecting food intake, but also the regulation of fat oxidation and storage in liver, skeletal muscle, and adipose tissue. Summary Metformin induces modest weight loss in overweight and obese individuals at risk for diabetes. A more detailed understanding of how metformin induces weight loss will likely lead to optimal co-prescription of lifestyle modification with pharmacology for the treatment of obesity independent of diabetes.
    Current Opinion in Endocrinology Diabetes and Obesity 08/2014; DOI:10.1097/MED.0000000000000095 · 3.77 Impact Factor